Compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. Pharmaceutical compositions comprising peptide sequences with high cytotoxicity to cancer cell lines are provided. A method for treating cancer is provided.

Described are compositions comprising enveloped viruses that are not MVA, a sulfate salt at a concentration of about 5 mM to about 300 mM and a buffer, and the composition has a pH of about 6.0 to about 8.5. It also discloses methods for stabilizing an enveloped virus composition by preparing said viral formulation.

The present invention provides peptide conjugates that target an integrin such as α.sub.vβ.sub.6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The peptide conjugates of the present invention are particularly useful for imaging a tumor, organ, or tissue. Compositions and kits containing the peptide conjugates of the present invention are also provided herein.

The present invention describes a compound of formula (I) which can be used in the diagnosis, treatment or prevention of neurotensin receptor-related conditions such as tumors and hematological malignancies. ##STR00001##

Integrin ligands having serum stability and affinity for αvβ6 integrins are described. Compositions comprising αvβ6 integrin ligands having serum stability and having affinity for αvβ6 integrins and methods of using them are also described.

A method for removing precursors in recombinant human nerve growth factor (rhNGF) by hydrophobic interaction chromatography (HIC) is provided, where a Chinese hamster ovary (CHO) cell culture is processed by column chromatography for preliminary purification, and the pretreated sample obtained therefrom is further processed in a HIC column by washing the sample and then eluting the HIC column.

The present disclosure includes a PINK1-C-terminal domain (PINK1-CTD) polypeptide that binds to ERBB tyrosine kinase domain (ERBB-TKD) and therefore impedes ERBB from dimerization and activation. The PINK1-CTD polypeptide inhibits, prevents and/or treats ERBB-expressing cancers. The disclosure demonstrates the anti-tumor function of the PINK1-CTD, which provides a new direction for ERBB-expressing cancer therapy.

Embodiments concern methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. Aspects include methods and compositions for providing a passive immune response against the bacteria. In certain embodiments, the methods and compositions involve an antibody that binds Coagulase (Coa). Further aspects relate to immunogenic compositions comprising at least one Staphylococcal coagulase R Domain, wherein the R Domain is 80% identical in sequence to a R Domain.

The invention describes peptide ligands specific for human plasma Kallikrein.

Compositions, devices and methods are described for improving adhesion, attachment, and/or differentiation of cells in a microfluidic device or chip. In one embodiment, one or more ECM proteins are covalently coupled to the surface of a microchannel of a microfluidic device. The microfluidic devices can be stored or used immediately for culture and/or support of living cells such as mammalian cells, and/or for simulating a function of a tissue, e.g., a liver tissue, muscle tissue, etc. Extended adhesion and viability with sustained function over time is observed.